Описание
INN: Enoxaparin sodium
Presentation: solution for injections 10000 anti-Xa IU/ml, 0.2 ml, 0.3 ml, 0.4 ml, 0.5 ml, 0.6 ml, 0.7 ml, 0.8 ml, 1, 0 ml disposable syringes 5 units per pack
By prescription
Pharmacotherapeutic group: direct-action anticoagulant
Therapeutic indications:
• prevention of venous thrombosis and embolism during surgical interventions in patients of moderate and high risk, especially in orthopaedic and general surgical interventions, including oncological interventions;
• prevention of venous thrombosis and embolism in bed rest patients due to acute therapeutic diseases, including acute heart failure and decompensation of chronic heart failure (NYHA class III or IV), respiratory failure, as well as at severe infections and rheumatic diseases at an increased risk of venous thrombus formation;
• treatment of deep vein thrombosis with pulmonary embolism or without pulmonary embolism, except for cases of pulmonary embolism requiring thrombolytic therapy or surgery;
• prevention of thrombus formation in the extracorporeal circulation system during haemodialysis; Acute coronary syndrome:
• treatment of unstable angina pectoris and non-ST segment elevation myocardial infarction in combination with oral administration of acetylsalicylic acid;
• treatment of acute ST-segment elevation myocardial infarction in patients undergoing medical treatment or subsequent percutaneous coronary intervention (PCI).
• prevention of venous thrombosis and embolism in bed rest patients due to acute therapeutic diseases, including acute heart failure and decompensation of chronic heart failure (NYHA class III or IV), respiratory failure, as well as at severe infections and rheumatic diseases at an increased risk of venous thrombus formation;
• treatment of deep vein thrombosis with pulmonary embolism or without pulmonary embolism, except for cases of pulmonary embolism requiring thrombolytic therapy or surgery;
• prevention of thrombus formation in the extracorporeal circulation system during haemodialysis; Acute coronary syndrome:
• treatment of unstable angina pectoris and non-ST segment elevation myocardial infarction in combination with oral administration of acetylsalicylic acid;
• treatment of acute ST-segment elevation myocardial infarction in patients undergoing medical treatment or subsequent percutaneous coronary intervention (PCI).
Shelf life: 2 years
Документы